CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur
|
|
|
- ありさ あさま
- 5 years ago
- Views:
Transcription
1 CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella pneumoniae genes Serratia marcescens Proteus mi rabilis Proteus vulgaris Providencia calco aceticus Haemophilus influenzae Imipenem (MK-0787), ceftizoxime (CZX), latamoxef (LMOX), cefoperazone (CPZ), cefmetazole (CMZ), cefsulodin (CFS), ceftazidime (CAZ), piperacillin(pipc), sulbenicillin (SBPC)genta-
2 VOL. 33 S-4 CHEMOTHERAPY Table 1 Antibacterial spectrum of MK-0787, CPZ, CZX, LMOX and PIPC Gram-positive bacteria Inoculum size: 106cells/ml MIC (Đg/ml) *Sensitivity test agar supplement with 10% horse blood Table 2 Antibacterial spectrum of MK-0787, CPZ, CZX, LMOX and PIPC Gram-positive bacteria Inoculum size: 108 ells/ml MIC (Đg/ml) *Sensitivity test agar supplemented with 10% horse blood Streptococcus Corynebacterium diphtheriae H. influenzae
3 CHEMOTHERAPY NOV. 198B Table 3 Antibacterial spectrum of MK-0787, CPZ, CZX, LMOX and PIPC Gram-negative bacteria MIC (Đg/ml)
4 CHEMO THERAPY Table 4 Antibacterial spectrum of MK-0787, CPZ, CZX, LMOX and PIPC Gram-negative bacteria Inoculum size: 108 cells/mlmic *Gonococcus medi um (fig/m1)
5 CHEMOTHERAPY Table 5 Antibacterial spectrum of MK-0787, CPZ, CZX, LMOX and PIPC anaerobic bacteria Inoculum size: 108 cells/m1mic (peml) Table 6 Antibacterial spectrum of MK-0787, CPZ, CZX, LMOX and PIPC Anaerobic bacteria Inoculum size: 108 cells/mlmic (pg/m1)
6 CHEMO THERAPY Fig. 2 Sensitivity distribution of clinical isolates S. aureus (42 strains) Fig. 4 Sensitivity distribution of clinical isolates. E. coli (59 strains) Fig. 3 Sensitivity distribution of clinical isolates S. pyogenes (31 strains) Fig. 5 Sensitivity distribution of clinical isolates K. pneumoniae (59 strains)
7 CHEMO THERAPY Fig. 6 Sensitivity distribution of clinical isolates E. cloacae (30 strains) Fig. 8 Sensitivity distribution of clinical isolates S. marcescens (52 strains) Fig. 7 Sensitivity distribution of clinical isolates Fig. 9 Sensitivity distribution of clinical isolates E. aerogenes (34 strains) P.mirabilis (32 strains)
8 CHEMO THERAPY Fig.10 Sensitivity distribution of clinical isolates Fig. 12 Sensitvity distribution of clinical isolates P.ulgaris (32 strains) M. morganii (25 strains) Fig.11 Sensitivity distribution of clinical isolates Fig. 13 Sensitivity distribution of clinical isolates P.rett geri (15 strains) P.aeruginosa (40 strains)
9 CHEMO THERAPY Fig.14 Sensitivity distribution of clinical isolates Fig.16 Sensitivity distribution of clinical A. calcoaceticus (44 strains) GMr, SBPCr P.aeruginosa (37 strains) Fig.15 Sensitivity distribution of clinical isolates Fig.17 Sensitivity distribution of clinical H. influenzae (48 strains) CFSr P.aeruginosa (35 strains)
10 CHEMO THERAPY Table 7 Antibacterial activity of MK-0787 *80% Inhibitory concentrations of MK-0787, CZX, CMZ and LMOX Table 8 Antibacterial activity of MK-0787 on GM, SBPC and CFS resistant P. aeruginosa
11 CHEMO THERAPY Table 9 Influence of inoculum size on the antibacterial activity of MK-0787 MIC: ml Table 10 Influence of medium ph on the antibacterial activity of MK-0787 Inoculum size : 10 cells/m1 MIC: ml
12 CHEMOTHERAPY Table 11 Influence of horse serum on the antibacterial activity of MK-0787 Inoculum size: MIC: pg/m1 106 cells/1-n] Fig. 18 Effect of MK-0787 on the viability of S. aureus 209-P JC Fig. 20 Effect of MK-0787 on the viability of K. pneumoniae KC-1 Fig. 19 Effect of MK-0787 on the viability of E. coli K-12 Fig. 21 Effect of MK-0787 on the viability of S. marcescens T-55
13 CHEMOTHERAPY 86 Fig. 22 Effect of MK-0787 P. aeruginosa E-2 on the viability NOV μg/mlに of あ り,CFSの6.25μg/ml,CPZの12.5 μg/ml,gmの3.13お よ び50μg/ml,SBPCの12.5 お よ び100μg/mlよ 値 をTable8に 6.25μg/mlや り も優 れ て い た そ の 時 のMIC80 示 した 本 剤 は3.13μg/mlでCFSの 他 の比 較 薬 よ りも優 れ て いた 16)CFSrP. aeruginosaの 1983年 場合 に京 滋地 区 の 呼吸 器 感 染 症 患 者 よ り分離 され たP. aeruginosaの 中 で,CFS耐 性 の 結 果 をFig.17に 3.13μg/mlに 性35株 に 対 す る感受 示 し た 本 剤 の 感 受 性 の ピ ー クは あ り,GMは3.13μg/mi,CAZは025 μg/ml,cpzは25μg/ml,cfsは>100μg/mlで た MIC80値 あっ で み て も 本 剤 は3.13μg/mlで あ り,他 の 比較 薬 に比 べ て 明 らか に 優 れ て い た 3.抗 菌 力 に及 ぼ す 諸 因 子 の影 響 s209-p い た 14)H. influenzaeの Fig.15に iaekc-1お 場合 示 す よ う にMK-0787の 0.78μg/mlに 感 受 性 ピー ク値 は り劣 り,CMZの6.25μg/mlよ た MIC80値 の 比 較 で も,本 り優 れ て い 剤 は3.13μg/mlで あ り, CZXの0.05μg/mlやLMOXの0.2μg/mlよ り劣 っ て い た 15)GMｒ,SBPCrP. aeruginosaの Fig.16に Fig. 示 す よ うにMK-0787の 23 Phase-contrast よ びP. aeruginosae-2を 力 に 及 ぼ す 培 地pH,馬 場 合 感 受 性 ピー ク値 は micrographs of E. coli 9 11に pneumo-n 用 い て,抗 菌 血 清 添 加,接 CZX,LMOX,CPZ,PIPCと あ り,CZXの0.05μg/mlやLMOXの 0.1μg/mlよ JC, E.coliNIHJJC-2,K. S.aureu 種菌量の影響を 比 較 した 結 果 をTable 示 した 本 剤 を 含 む す べ て の 薬 剤 は,い 菌 株 に お い て も,培 地pH,馬 ず れの 血 清 添 加 に お い て,MIC の 変 動 は ほ と ん ど 認 め ら れ な か っ た ま た 本 剤 は,接 種 菌 量 に よ る 影 響 を,S.aureusやP. aeruginosaで はほと ん ど 受 け な か っ た が,E.coli,K.pneumoniaeで は菌量 の 増 加 に 伴 い,感 K-12 exposed to 受 性 は 若 干 低 下 し た 一 方 比 較 薬 とし MK-0787 for 3 hours at 37 Ž
14 VOL. Fig. Fig CHEMOTHERAPY S-4 Phase-contrast 25 Phase micrographs contrast micrographs of S. of P. inarcescens aeruginosa 87 T-55 exposed to MK-0787 for 3 hours at 37 Ž E-2 exposed to MK-0787 for 3 hours at 37 Ž
![CHEMOTHERAPY 88 て 用 い たPIPC,CZX,LMOXで よ びP. aeruginosaに NOV.1985 Fig. 27 はK.pneumoniaeお お い て 接 種 菌 量107 108celles/ml Fluorography showing competition of MK-0787 for [14C]-PCG binding in P.](/docs-images/95/124246330/images/15-0.jpg "aeruginosa E-2 で菌 量 に よ る影響 が み られ た 4.殺 菌作用 Fig.18に 示 した よ う に,Smrm5に 0787は107,108cells/ml接 対 してMK- 種 共 にMIC(0.013μg/ml) 以 上 の 濃 度 で 殺 菌 的 に 作 用 した ooliやk.pneumoniaeに Fig.20に 対 E. し て は,Fig.")
15 CHEMOTHERAPY 88 て 用 い たPIPC,CZX,LMOXで よ びP. aeruginosaに NOV.1985 Fig. 27 はK.pneumoniaeお お い て 接 種 菌 量 celles/ml Fluorography showing competition of MK-0787 for [14C]-PCG binding in P. aeruginosa E-2 で菌 量 に よ る影響 が み られ た 4.殺 菌作用 Fig.18に 示 した よ う に,Smrm5に 0787は107,108cells/ml接 対 してMK- 種 共 にMIC(0.013μg/ml) 以 上 の 濃 度 で 殺 菌 的 に 作 用 した ooliやk.pneumoniaeに Fig.20に 対 E. し て は,Fig.19お 示 した よ う にMK-0787の (い ず れ も0.78μg/ml)以 よび そ れ ぞ れ のMIC 上 の 濃 度 でdoseresponseの あ る殺 菌 作用 が み られ た marcescensの 場 合 は,Fig.21に S. 量 が107cells/mlの 示 した よ う に,菌 場 合,MIC(3.13μg/ml)以 で 殺 菌 作 用 が 見 ら れ た が,108cells/mlの 上 の 濃度 菌 量 で はを の 殺 菌 性 が 減 弱 す る傾 向 を 認 め た P.P. aeruginosaに MIC(1.56μg/ml)以 Smrm3の 対 して はFig.22に 示 した よ う に 上 の 濃 度 で 殺 菌 作 用 が み られ た が, 場 合 と 同 様doseresponseは あ ま り顕 著 で 溶 菌 象 も観 察 され た は な か った 5.位 対P.すaeruginosa る 形 態 変 化 の 結 果 をFig.25に 相 差 顕 微鏡 に よる形 態 観 察 coliに 対 す るMK-0787の し た 0.013お 示 した 0.1μg/mI作 示 い く様 子 が 観 察 され,0.39,0,78,1.56(MIC) 用 で はcontrolと 同 6.25μg/ml作 よ び0,025μg/ml作 様 に 増 殖 して い く様 子 が,0.05,0.1お よ び0,39μg/ml 6.PBPsに coliお 用 では 菌 体 の球 形 化 や 溶菌 像 を観 察 す る こ とが で きた 0787の S.marce scensに 対 す る 形 態 変 化 の 結 果 をFig.24に した 0.19,0.39,0.78μg/ml作 び12.5μg/ml作 Fig. 26 用 で はbulge状 示 用 で は菌 は 増 殖 しな が ら 球 形 化 して い く様 子 が 観 察 さ れ,3.13(MIC)お,3.13, の 細 胞 やspheroplast様 対 す る親 和 性 よ びP. aeruginosaのpbpsに E. 親 和 性 をFig.26お 対 す るMK- よ びFig.27に,そ シ ト メ ー タ ー 処 理 に よ り 得 た50%阻 12に よ の細 胞 や 球 形 化 そ して Fluorography showing competition of MK-0787 for [14C]-PCG binding in E. coli K-12 用 で はbulge状 同 様 に増 殖 して 構 造 そ して溶 菌像 が 観 察 され た 作 用 で は 菌 体 の 球 形 化 が 観 察 さ れ た ま た0.78(MIC) μg/ml作 用 で はcontrolと 形E. 態 変 化 をFig.23に 示 した coliに 3の して デ ン 害 濃 度 をTable 対 E. し てMK-0787はPBPsの2 順 に 良 好 な 親 和 性 を 示 し,そ 度 は,1a,1bs, れ ぞ れ の50%阻 く0.008,0.008,0.048,0.48で 害濃 あ っ た ま たP. に 対 して はPBPご52=1bs,1a,3の 良 好 な 親 和 性 を 示 し,そ の50%阻 <0.008=<0.008,0.0094,0 0105で III.総 新 しい β-lactam系 加vitro抗 aeruginosa 順に 害 濃度 は そ れ ぞ れ あ った 括 お よび 考 察 抗 生 剤 で あ るMK-0787に 関す る 菌 力 に つ い て 検 討 を 行 っ た 本 剤 は,グ ラム 陽 性 菌 お よ び グ ラ ム 陰 性 菌 に 幅 広 い 抗 菌 ス ペ ク トラム を 有 し,Bacteroidesに も 抗 菌 力 を 示 した グ ラム陽 性 菌 に は 比 較 薬 と して 用 い たCMZ,CTZ,LMOXよ りも 良 好 な 抗 菌 力 を 示 し た グ ラ ム 陰 性 菌 で はP. aeruginosa,a. calcoaceticusお よ びA.faecalisに は 比較薬 より も優 れ た 抗 菌 力 を 示 し た が,E.coli,K.pneumoniae, Prolmε 属 で は,比 較 薬 に 比 べ て 抗 菌 力 が 若 干 低 か った ま た,P. maltophiliaに はSAINOら7)の は 抗 菌 力 を 示 さ な か っ た これ 報 告 し て い る よ う に,P. maltophiliaが
16 VOL. 33 S-4 CHEMOTHERAPY Table 12 Competition of MK-0787 with 14C-labeled penicillin G for binding to PBPs in cytoplasmic membranes of E. coli K-12 and P. aeruginosa E-2 in vivo * Concentration as amolar ratio to 14C-labeled penicillin G required for 50% inhibition binding of labeled penicillin G 2) NASU, M.; J. P. MASKELL, R. J. WILLIAMS & J. D. WILLIAMS: In vitro activity of MK 0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp. Antimicrob. Agents Chemother. 20: 433 `436, ) NEU, H. C. & P. LABTHAVIKUL: Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its p-lactamase stability. Antimicrob. Agents Chemother. 21: , 1982 Chemotherapy 27: 559 `560, ) SPRATT, B. G.; Distinct penicillin binding proteins involved in the division, elongation and shape of Escherichia coli K-12. Proc. Natl. Acad. Sci., U. S. A. 72: , ) SAINO, Y. ; F. KOBAYASHI, M. INOUE & S. MI- 1) KROPP, H.; J. G. SUNDELOP, J. S. KAHAN, F. M. KAHAN & J. BIRNBAUM: MK 0787 (N-formimidoyl thienamycin) : Evaluation of in vitro and in vivo activities. Antimicrob. Agents Chemother. 17: 993 `4000, 1980 TSUHASHI: Purification and properties of inducible penicillin Ĉ-lactamase isolated from Pseudomonas maltophilia. Antimicrob. Agents Chemother. 22 : , 1982 Chemotherapy 28 (S-7): 35-41, ) HASHIZUME, T.; F. ISHINO, J. NAKAGAWA, S. TAMAKI & M. MATSUHASHI: Studies on the mechanism of action of imipenem(n-formimidoyl thienamycin) in vitro: Binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa and inhibition of enzyme activities due to the PBPs in E. coli. J. Antibiot. 37: 394 `400, 1984
17 CHEMOTHERAPY NOV IN VITRO ACTIVITY OF IMIPENEM, A NEW CARBAPENEM TAKESHI NISHINO, KAZUNORI NAKAMURA, MAYUMI TANAKA, TOSHIMI GOTOH MASAKO OHTSUKI and TERUO TANINO Department of Microbiology, Kyoto Pharmaceutical University The bacteriological evaluation of imipenem(mk-0787), a new S-lactam antibiotic, was studied. the following results were obtained. MK-0787 showed a broad antibacterial spectrum against gram-positive, gram-negative bacteria with the exception of P. maltophilia and Bacteroides. The antibacterial activity of MK-0787 against gram-positive bacteria was superior to that of cefinetazole, ceftizoxime and latamoxef. It inhibited gram-negative bacteria resistant to other agents. It did not show cross resistance for gentamicin or cefsulodin resistant P. aeruginosa. There was minimal effect of inoculum size of E. coli and K. pneumoniae, and medium ph or horse serum had no effect on activity. Time-kill curve confirmed a dose response bactericidal activity of MK In morphological observation of E. coli and P. aeruginosa by phase contrast microscope, exposure to MK-0787 resulted in the formation of spherical cells, bulge forms and spheroplast-like structures. MK-0787 showed a high affinity for PBPs 2 of E. coli and P. aeruginosa.
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
CHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC
![VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC](/thumbs/95/124246112.jpg "VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC")
VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC, E. coli NIHJ JC-2 pneumoniae E. coli 106, K. pneumoniae
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.
pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P. aeruginosa 30, P. maltophilia pyogenes 32, Escherichia
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1
Levloxacin V.:1 Z iiiir fa L CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d. 0.39 Đg/ml, 2h; e b b. 0.10 Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1992 0.39 Đg/ml, and Fig.
VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
CHEMOTHERAPY MAY 1988 Table 1 Media used for preculture and MIC determination *BHIB: Brain heart infusion broth (Difco), B-NAD: B-Nicotinamide adenine dinucleotide (Sigma chemical Co.), GAMB GAM broth
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
CHEMOTHERAPY 34 T-2588の APR.1986 嫌 気 性 菌 に 対す る抗 菌 作 用 に つ い て 沢 赫 代 神 野 英 毅 青 木 誠 小 林 と よ子 渡 辺 邦 友 上 野 一 恵 岐阜大学医学部附属嫌気性菌実験施設 新 し く 開 発 さ れ た 経 口 用 エ ス テ ル 型 セ フ ェ ム 系 抗 生 剤T-2588の 口 剤 で あ るcephalexin(CEX),cefaclor(CCL)
VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6
![VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6](/thumbs/101/149863612.jpg "VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6")
VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6- O-[3-deoxy-4 -C-methyl-3 -(methylamino) -ƒà-l- arabinopyranosyl]-2
Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,
Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227, P. putrefaciens 279 A. faecalis 120, A. ordrans 114
CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacilli
Key words: Pseudomonas aeruginosa, fosfomycin, ofloxacin, Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacillin,
JUNE 1988
JUNE 1988 VOL.36 S-2 CHEMOTHERAPY Table 1. Antibacterial activity of NY-198 against standard strains of bacteria By the agar-dilution method (inoculum: 106 CFU/ml) JUNE 1988 Fig. 3. Antibacterial activity
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1
2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1 VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table
Fig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
2 CHEMOTHERAPY JAN. 1976 VOL. 24 NO. 1 CHEMOTHERAPY 3 Table 1 Antibacterial spectra of Cephacetrile, Cephalothin, Cephaloridine and Cefazolin 4 CHEMOTHERAPY JAN. 1976 Fig. 1 In vitro activity of Cephacetrile,
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali
CHEMOTHERAPY DEC. 1988 (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis Pseudomonas aeruginosa, Serratia ma- Fig. 1. Chemical
CHEMOTHERAPY SEPT. 1970
CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY 691 692 CHEMOTHERAPY SEPT. 1970 VOL. 78 NO. CHEMOTHERAPY 5 写 真1 第1病 693 写 真4 日 In vitroの しCEZの 第22病
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
VOL. 28 S-2 CHEMOTHERAPY
VOL. 28 S-2 CHEMOTHERAPY CHEMOTHERAPY 52 (Oxaciliin hydrolysing Enterobacter cloacae P.mirabilis GN79, sp.gn69,お enzyme)の Nek E.ooli よ びE.coli た GN番 産 生 菌 と し て, 39, Proteus CSH vulgaris 2 (RK1), ML1410
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
CHEMOTHERAPY NOV Fig.1 Combined effect of drug A and drug B Fig. 2 MICs of CEPs (LMOX, CZX, CMX, CPZ) against 27 strains (inoculum size 106 CFU/
CHEMOTHERAPY NOV. 1987 Fig.1 Combined effect of drug A and drug B Fig. 2 MICs of CEPs (LMOX, CZX, CMX, CPZ) against 27 strains (inoculum size 106 CFU/ml) of S. marcescens + Visible growth No visible growth
Pseudomonas aeruginosa S-827 Fig. 1. Method of biofilm formation. Table 1. Susceptibilities of antimicrobial agents on agar plate and in broth against Pseudomonas aeruginosa S-827 JULY CHEMOTHERAPY 888
- 1 -
- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum
VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae methicillin-resistant Staphylococcus
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
CHEMOTHERAPY
VOL.40 S-1 coagulase negative Staphylococcus sp, methicillin- resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Enterobacter
Mueller-Hinton broth), Streptococcus pneumoniae (S. pneumoniae), Streptococcus faecalis (S. faecalis)
Fig. 1 Chemical structure of TA-058 (2S, 5R, 6R)-6- k2r-2- (2R-2- amino-3-n- methyl carbamoylpropionamido) -2- (4- hydroxyphenyl) acetamido l-3, 3-dimethy1-7-oxo- 4-thia-1- azabicycio k3.2,0 l heptane-2-carboxylic
VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of
VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of 4.9 g Mezlocillin Streptococcus pneumonzae pneumoniae
co Kanamycin (KM), Streptomycin (SM), Fradiomycin Table 2. Comparison of antibacterial activity of 3', 4'-dideoxykanamycin B with that of other antibi
Fig. 1. Chemical structure of 3', 4'-dideoxykanamycin B co Kanamycin (KM), Streptomycin (SM), Fradiomycin Table 2. Comparison of antibacterial activity of 3', 4'-dideoxykanamycin B with that of other antibiotics
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,
Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
ｽﾗｲﾄﾞ ﾀｲﾄﾙなし
第 4 回ひびき臨床微生物シンポジュウム June 24,27, 港ハウス 感受性検査を読む ( 同定検査結果確認やスクリーニング検査と捉えて ) ( 株 ) キューリン小林とも子 キューリン微生物検査課 塗抹鏡検グラム染色 分離培養検査血液 BTB, エッグーヨーク 報告書作成結果承認 同定検査 VITEK TSI,LIM クリスタル NF 薬剤感受性検査 MIC2 ディスク法 薬剤感受性結果 (
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det
Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not detected *: time after last administration Table 2. Concentration
CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized